Pancreatic Cancer Research

ResearcherTianjin Medical University Cancer Institute and HospitalActive in the last 2 years

Yuexiang Liang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5201-8187; OpenAlex author ID A5090242405. Sources: OpenAlex.

Their work

Papers
17 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
28
Papers, trials and grants by year

2023: 7 papers · 2024: 5 papers · 2025: 3 papers · 2026: 2 papers

Papers 17

  1. Development and Prospective Validation of a Cell-free DNA-Based Model for the Early Detection of Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-25-0323↗
  2. TNM stage I pancreatic ductal adenocarcinoma patients without pathological risk may drive limited benefit from adjuvant chemotherapy. Co-author DOI 10.3389/fmed.2026.1914610↗
  3. Prognostic Significance of C-Reactive Protein or Prealbumin in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.jss.2024.12.047↗
  4. A Preoperative Model for Predicting Lymphovascular Invasion in Pancreatic Ductal Adenocarcinoma. First author DOI 10.1016/j.jss.2025.06.081↗
  5. Integrated pretreatment stratification system for pancreatic cancer: combining anatomical resectability and tumor biological parameters. First author DOI 10.20892/j.issn.2095-3941.2025.0213↗
  6. Revealing splenectomy-driven microRNA hsa-7b-5p's role in pancreatic cancer progression. Co-author DOI 10.1016/j.isci.2024.109045↗
  7. Survival outcomes of adjuvant chemotherapy in patients with stage I pancreatic cancer stratified by pathologic risk. Co-author DOI 10.1016/j.surg.2024.07.047↗
  8. Nomogram model for predicting early recurrence for resectable pancreatic cancer: A multicenter study. Co-author DOI 10.1097/md.0000000000037440↗
  9. Fibrinogen to pre-albumin ratio is an independent prognostic index for patients with pancreatic ductal adenocarcinoma after radical resection. Co-author DOI 10.1186/s12957-024-03524-0↗
  10. Prognostic significance of grade of malignancy based on histopathological differentiation and Ki-67 in pancreatic ductal adenocarcinoma. Co-author DOI 10.20892/j.issn.2095-3941.2023.0363↗
  11. Biological risk based on preoperative serum CA19-9 and histological grade predicts prognosis and improves accuracy of classification in patients with pancreati… Co-author DOI 10.1002/cnr2.1911↗
  12. Prognostic nutritional score based on pretreatment lymphocyte, platelet, and prealbumin predicts prognosis in patients with pancreatic cancer. Co-author DOI 10.1002/jso.27362↗
  13. A new staging system for postoperative prognostication in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.isci.2023.107589↗
  14. Elevated preoperative plasma D-dimer level was an independent prognostic factor for patients with PDAC after curative resection: a retrospective analysis. First author DOI 10.1093/jjco/hyad090↗
  15. Impact of preoperative CA19-9 and histology grade on prognosis of pancreatic ductal adenocarcinoma and its value in TNM stage Co-author DOI 10.21203/rs.3.rs-2653528/v1↗
  16. Biological risk based on preoperative serum CA19-9 and histology grade predicts prognosis in patients with pancreatic cancer Co-author DOI 10.22541/au.168681252.23358138/v1↗
  17. Presence of tumor deposits is an indicator of poor prognosis in patients with pancreatic ductal adenocarcinoma. Co-author PMID 37293176↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shaofei Chang · 12 shared papers, 2023–2025 · strength 2.62
  2. Quan Man · 9 shared papers, 2023–2025 · strength 1.95
  3. Tiansuo Zhao · 7 shared papers, 2023–2026 · strength 1.48
  4. Song Gao · 6 shared papers, 2023–2025 · strength 1.43
  5. Yiping Zou · 6 shared papers, 2023–2025 · strength 1.35
  6. Jihui Hao · 5 shared papers, 2023–2026 · strength 1.00
  7. Chuntao Gao · 4 shared papers, 2024–2026 · strength 0.97
  8. Haorui Li · 4 shared papers, 2023–2025 · strength 0.87
  9. Song Gao · 3 shared papers, 2024–2026 · strength 0.63
  10. Xiuchao Wang · 3 shared papers, 2024–2026 · strength 0.61
  11. Li Zhifei · 2 shared papers, 2023–2026 · strength 0.55
  12. Jun Yu · 2 shared papers, 2025–2026 · strength 0.42
  13. Yongjie Xie · 2 shared papers, 2024 · strength 0.40
  14. Shiye Ruan · 1 shared paper, 2025 · strength 0.28
  15. Junjin Wang · 1 shared paper, 2024 · strength 0.26
  16. Xugang Sun · 1 shared paper, 2025 · strength 0.26
  17. Yu Guo · 1 shared paper, 2025 · strength 0.26
  18. Chuntao Gao · 1 shared paper, 2023 · strength 0.22
  19. Guannan Sheng · 1 shared paper, 2024 · strength 0.21
  20. Liangliang Wu · 1 shared paper, 2024 · strength 0.21
  21. Peng Jin · 1 shared paper, 2024 · strength 0.21
  22. Xiaona Wang · 1 shared paper, 2024 · strength 0.21
  23. Bin Li · 1 shared paper, 2024 · strength 0.21
  24. Bo Ni · 1 shared paper, 2024 · strength 0.21
  25. Meng Zhang · 1 shared paper, 2026 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.